Practical Aspects of Drug Testing in Human Hair



Similar documents
FREQUENTLY ASKED QUESTIONS Hair Testing

FREQUENTLY ASKED QUESTIONS Oral Fluid Drug Testing with Oral-Eze

Frequently asked Questions

Collection Instructions for ARUP Drug Screen Kit #49204

The Science of Hair Testing Summary of Literature Review. Presented by SAMHSA s Division of Workplace Programs

Advantages & Disadvantages of Drug Testing in Alternative Matrices

Drug and Alcohol Testing in Hair, Collection and Analysis

DUI in Southern Ohio MATT 2006

Drug Testing for Criminal Justice Involved Individuals in Michigan

The potential of oral fluid as a specimen in various drug testing programs

CUT-OFF CONCENTRATIONS FOR DRUGS OF ABUSE IN SALIVA FOR DUI, DWI OR OTHER DRIVING-RELATED CRIMES

Confirmation by Triple Quadrupole LC/MS/MS for HHS-compliant Workplace Urine Drug Testing

Interlaboratory Studies on the Analysis of Hair for Drugs of Abuse: Results from the Fourth Exercise

Improved Method for the Analysis of 31 Drugs of Abuse in Oral Fluid samples using the Thomson extreme FV by LC-MS/MS

Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain (CNCP)

Technical Note. Introduction. Edward J. Cone. Lance Presley, Michael Lehrer, William Seiter, and Melissa Smith

EFFECTIVE DATE: February 12, 2010, unless a later date is cited at the end of a section. [ NMAC - Rp, NMAC, 02/12/2010]

Central Government Laboratory Department of Health and Environment

Drug Utilization Is On The Rise

DRUG SCREENING POLICY AND PROCEDURES Effective August 31, 2015

What Does the Drug Test Tell Us

Simultaneous Quantitation of 43 Drugs in Human Urine with a Dilute-and-Shoot LC-MS/MS Method

Pennsylvania Hospital & Surgery Center ADMINISTRATIVE POLICY MANUAL

Opiates in Urine by SAMHSA GC/MS

Hillsborough Community College - Ybor City Campus 1025C Laboratory Exercise 9: Testing Urine for the Presence of Drugs Introduction

PHOENIX FIRE DEPARTMENT ALCOHOL AND SUBSTANCE ABUSE EDUCATION, AWARENESS, TREATMENT & PREVENTION PROGRAM PROCESS PROCEDURE

Toxicology CPT Code Changes for 2016

LC-MS for Pain Management Support. Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories

LC-MS for Pain Management Support

LC Application Note.

This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics

Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications

BEST PRACTICES IN DRUG TESTING OF HEALTHCARE PROFESSIONALS

Comprehensive LC/MS Analysis of Illicit and Pain Management Drugs, Including Their Metabolites, in Urine

NALCOR ENERGY ALCOHOL AND DRUG PROGRAM REQUIREMENTS FOR CONTRACTORS

Opium Smoke: The Study of Second- and Third-Hand Exposure in Women and Children of Afghanistan

Drug Testing Reference Tables for Drug Courts

Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications

PtProtect Pain Medication Management Program Monitors Patient Compliance

Urine Drug Testing Methadone 101 Methadone for hospitalists

Technical Procedure for the Solid Phase Extraction of Acidic, Neutral and Basic Drugs for GC-MS Analysis

One Source Toxicology Laboratory, 1213 Genoa Red Bluff, Pasadena, Texas 77504

Why do employers drug test? How is drug testing conducted and how accurate is it?

Appropriate Use of UDT to Improve Patient Care

REACH AIR MEDICAL SERVICES SUBSTANCE ABUSE POLICY FOR APPLICANTS APPLYING FOR SAFETY-SENSITIVE POSITIONS

Department of Health and Human Services. No. 94 May 15, Part II

Hair Drug & Alcohol Testing FAQs

Clinical Drug Testing in Primary Care

CITY OF MONTEREY Substance Abuse Policy General Employees of Monterey (GEM) July 1, 2003

2013 Annual Toxicology Report

EMPLOYEE DRUG SCREENING: What You Need to Know!

Indiana State Department of Toxicology 2012 Annual Report

Author: Leo Cangianelli, The Walsh Group, 6701 Democracy Blvd., Suite 300, Bethesda, MD 21807, U.S.A.

AppNote 6/2011. Determination of Pain Management Drugs using Automated Disposable Pipette Extraction and LC-MS/MS KEYWORDS ABSTRACT

Oral Fluid Testing: Promises and Pitfalls

Volume 22 Number 22. C43-A ISBN ISSN Gas Chromatography/Mass Spectrometry (GC/MS) Confirmation of Drugs; Approved Guideline

Rationale for Urine Drug Testing (UDT)

Appropriate utilization of drug tests for pain management patients

Analysis of Drugs of Abuse in Biological Specimens

Understanding Drug Screens & PharmCAS Drug Screening Program Overview. Suzi Arant, Senior Business Developer July 8, 2011

A Generic LC-MS Method for the Analysis of Multiple of Drug of Abuse Classes with the Thermo Scientific Exactive TM System

Alcohol, Drug and Mental Health Services Alcohol & Drug Program County of Santa Barbara DRUG TESTING POLICY & PROCEDURES

Drug Abuse Trends Minneapolis/St. Paul, Minnesota

Bermuda Hospitals Board Drug Screening Programme

Drug Screens and the Medical Review Officer

Determination of Tapentadol and its Metabolite N

Rapid Screening Method for Illicit Drugs, Using an Advanced Solid Core UHPLC Column and UHPLC System with MS/MS Detection

APPLICATIONS MANUAL. Ifosfamide in blood serum Ingredients in blood serum Organophosphorus pesticides in tea leaf... 5

Prevalence and risk of driving under influence of psychoactive substances: Results from epidemiological studies

How Much Does a Random Student Drug Testing (RSDT) Program Cost?

THE DRUG AND ALCOHOL SCREENING PROGRAM

Date: July 20, 2011 Supersedes: PS E (4/28/2010) Subject: Drug Testing of Inmates

Forensic toxicology testing is requested in many situations. These

Employee Substance Abuse

Tandem mass spectrometry: a helpful tool in hair analysis for the forensic expert

71858 Federal Register / Vol. 73, No. 228 / Tuesday, November 25, 2008 / Notices

Alcohol and Drug Policy Model

Urine Drug Testing. Clinical Practice

Quantitative analysis of multiple illicit drugs in preserved oral fluid by solid-phase extraction and liquid chromatography tandem mass spectrometry

THE COLLEGE OF WESTERN IDAHO PTE PROGRAMS DRUG FREE SCHOOL POLICY

A Report on Marijuana and Prescription Drugs

CERTIFICATE OF COMPLIANCE OF

Drug Testing to Support Pain Management

The CPT code for Human papillomavirus (HPV) has changed from to This code (87624) covers testing for HPV High Risk genotypes.

Urine Drug Toxicology and Pain Management Testing. Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA

Employer Drug Testing Solutions

How To Test For Drugs And Alcohol

INNOVATIONS IN SUBSTANCE ABUSE TESTING

OU MEDICAL CENTER Human Resource Policy and Procedure Manual. Subject: Drug and Alcohol

Transcription:

Practical Aspects of Drug Testing in Human Hair Laboratory Perspective James A. Bourland, Ph.D., DABFT FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION

Overview of Collection Process FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 2

Hair Collection Site of Collection - Occipital Crown / Posterior Vertex Cut with Scissors in 2-3 locations close to the scalp Hair aligned in collection container root and distal ends FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 3

Hair Collection Challenges No head hair Body Hair Weaves Short Head Hair Contamination Claims Variability cutting from the scalp FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 4

Preparing Hair Collection Kit Alcohol prep used to clean scissors Hair collected from at least 3 regions occipital crown area Root ends aligned in the foil Foil placed inside the cardboard envelope Cardboard envelope initialed, dated and sealed Test request form/ chain of custody filled out Envelope placed into plastic bag Test request form placed in outer pocket of plastic bag Plastic bag sealed Specimen shipped to the laboratory FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 5

Overview of Accessioning Process FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 6

Overview Hair Accessioning Sample Arrives at lab Sample Sorting Process Hair Urine / Oral Fluid Accessioning Process Cut/ Weighed FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 7

Hair Accessioning Requirements Ideal to have Separate Area Isolated Each Station Scissors Cleaning Solution for Scissors Scale Sharpie Disposable Pads Accurate Scales Needed to Weigh hair Humidity Control (Reduce static electricity) FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 8

Aliquoting of Hair Hair cut at 3.9 cm from root end 3.9 cm segment of hairs cut into 2-5 mm segments Cut hair mixed for homogeneity 20 mg weighed 1 st aliquot: ELISA screen 2 nd aliquot: GC/MS and/or GC/MS/MS confirm

Pre-Analytical Process FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 10

Pre-Analytical Process Not a liquid Matrix Pre-Analytical Process Needed Prior to : Screening by Immunoassay Extraction for GC/MS, GC/MS/MS or LC/MS/MS Pre-Analytical Process should include Wash Procedure(s) to remove sources of external contamination Two main approaches Digestion of the hair matrix to a liquid Pre-Extraction of the Drug dissolved in a liquid Challenges Drugs and metabolites must remain intact Extraction or Digestion Efficiency Time Balance between Efficiency and TAT FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 11

Hair Confirmation: Extractions Cocaine and Amphetamines 4 washes Dilute Acid + Heat Extraction Opiates 4 washes Methanol/Buffer/KOH Digestion PCP 4 washes Methanol + Heat Extraction THC/THCA 4 washes NaOH + Heat Digestion All Drugs: SPE

Extraction FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 13

Extraction After Pre-analytical Process Extraction is similar to other matrices Solid Phase Extraction Liquid-Liquid Derivatization Deuterated Internal Standards Calibration Curve Quality Controls FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 14

Confirmation Technology GC/MS GC/GC/MS GC/MS/MS LC/MS LC/MS/MS FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 15

Drugs/ Metabolites Tested & Cut-Off Values in Hair FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 16

Quest Diagnostics DRUG CLASS INITIAL TEST LEVEL CONFIRMATORY LEVEL AMPHETAMINES Amphetamine Methamphetamine MDA MDMA 300 pg/mg 300 pg/mg 300 pg/mg 300 pg/mg 300 pg/mg COCAINE/METABOLITES Benzoylecgonine Cocaine Cocaethylene Norcocaine 300 pg/mg 300 pg/mg 300 pg/mg 300 pg/mg 300 pg/mg MARIJUANA THC Metabolite 1.0 pg/mg 0.1 pg/mg OPIATES Morphine Codeine 6-Acetylmorphine (6-AM) Hydrocodone* Hydromorphone* Oxycodone* Oxymorphone* 500 pg/mg 500 pg/mg 500 pg/mg 500 pg/mg 500 pg/mg 500 pg/mg 500 pg/mg 500 pg/mg FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 17

Omega Laboratories DRUG CLASS INITIAL TEST LEVEL CONFIRMATORY LEVEL AMPHETAMINES Amphetamine Methamphetamine MDA MDMA 500 pg/mg 500 pg/mg 500 pg/mg 500 pg/mg 500 pg/mg COCAINE/METABOLITES Benzoylecgonine Cocaine Cocaethylene Norcocaine 500 pg/mg 500 pg/mg 500 pg/mg 500 pg/mg 500 pg/mg MARIJUANA THC Metabolite 1.0 pg/mg 0.3 pg/mg OPIATES Morphine Codeine 6-Acetylmorphine (6-AM) Hydrocodone* Hydromorphone* Oxycodone* Oxymorphone* 300 pg/mg 300 pg/mg 300 pg/mg 300 pg/mg 300 pg/mg 300 pg/mg 300 pg/mg 300 pg/mg FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 18

Drug Test Results in Hair v. Urine FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 19

Combined Hair + Urine Profile Hair and Urine collected Urine 7-panel THC, Cocaine, Amps, Opiates and PCP Barbs and Ethanol Hair 5-panel THC, Cocaine, Amps*, Opiates and PCP *MDMA and MDA N = ~ 7,000 samples

Reason For Test 6000 5000 70.3% 4000 3000 2000 1000 0 12.9% 7.7% 6.5% 0.7% 0.5% 0.6% NM NR OT PA PE RA RC

Marijuana # of Positive Specimens 400 350 300 250 200 150 100 50 0 2.8% Hair + Urine 5.1% 4.0% 2.3% 1.2% Hair Urine Hair (T) Urine (T)

Amphetamines 600 500 6.1% # of Positive Specimens 400 300 200 2.4 % 4.6% 2.7% 100 0 Hair + Urine 0.3% Hair Urine Hair (T) Urine (T)

Cocaine # of Positive Specimens 400 350 300 250 200 150 100 50 0 1.2 % Hair + Urine 3.8% 0.04% 5.0 % 1.3% Hair Urine Hair (T) Urine (T)

Total : All Drug Categories (Combined Hair + Urine Profile) # of Positive Specimens 1400 1200 1000 800 600 400 200 0 6.5% Hair + Urine 17.1% 10.6% 9.6% 3.1% Hair Urine Hair (T) Urine (T)

Conclusions Drug Positive Rates: Higher in Hair v. Urine Most Dramatic Differences : Cocaine and Methamphetamine Pharmacokinetics Drug Use Patterns Combination of Both Matrices: Highest Detection Rate

INTERPRETATION ISSUES FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 27

Two Major Roadblocks: Interpretation????? EXTERNAL CONTAMINATION Use or Exposure? Many claims of exposure Marijuana Cocaine Hair Positives in Children Published studies showing Contamination HAIR COLOR BIAS Melanin Content Positives in Gray Hair Published studies showing Bias Approaches to combat claims Statistics Procedural Approaches to Combat Wash Procedures Metabolite Ratios FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 28

Methamphetamine Exposure Results 80 specimens: Methamphetamine only (no metabolite detected) 3 specimens: Amphetamine only 14 specimens : Methamphetamine Detected Amp < 50 pg/mg 20 specimens : Methamphetamine > 300 pg/mg and Amphetamine >50 pg/mg

20 Exposure Specimens: Methamphetamine Reportable 2 Specimens 5 month and 7 month old Prenatal Exposure? 15 specimens Ages 1-5 (8-2 year olds) Passive Ingestion? 1 specimen 7 year old 2 specimens 11 and 12 year old Drug Use?

Methamphetamine Adult Use Results 110 specimens met reporting criteria 6 specimens: amphetamine < 50 pg/mg 1 specimen: no amphetamine detected

Methamphetamine Parent / Metabolite Ratios: Adult v. Children (Exposure) Methamphetamine Amphetamine CHILDREN: Mean (pg/mg) 979 27 range 19-10,598 0-398 n = 114 114 ratio 36:1 ADULTS: Mean (pg/mg) 6944 663 range 204-62,170 0-8,083 n = 117 117 ratio 10:1

Methamphetamine in Hair: Adults v. Children 8000 6000 [pg/mg] 4000 2000 Adults Children 0 METH AMP Adults 6944 663 Children 979 27

Marijuana (THC) Exposure 126 requests for directed analysis for THC in children s hair (01/03-06/03) 104 samples positive for THC Mean Age = 4.15 years Age range (3 months to 16 years)

Marijuana (THC) Exposure Results 94 specimens: THC only (no metabolite detected) 1 specimen: THC < 5.0 pg/mg THCA > 0.1pg/mg 4 specimens THC Detected THCA < 0.10 pg/mg 5 specimens : THC > 5.0 pg/mg and THCA > 0.1 pg/mg

5 Exposure Specimens: Marijuana Reportable 2 Specimens 14 year old male and 16 year old female Drug Use? 3 specimens Ages 1-3 High Parent THC concentrations Passive Ingestion? 424.9/0.36; 188.5/0.10; 143.6/0.26

Marijuana (THC) Adult Use Results 88 specimens met reporting criteria 15 specimens: no THC metabolite detected 1 specimen: THC metabolite below reporting cut-off

Marijuana Parent / Metabolite Ratios: Adult v. Children (Exposure) THC THCA CHILDREN: Mean (pg/mg) 33.6 0.04 range 0.5-464.9 0-2.5 n = 104 104 ratio 840:1 ADULTS: Mean (pg/mg) 98.8 1.6 range 0-643.2 0-17.0 n = 104 104 ratio 62:1

Marijuana in Hair Adults v. Children 100 Adults Children [pg/mg] 50 0 THC THCA Adults 98.8 1.64 Children 33.6 0.04

Interpretation????? How many times did the person use in the last 90 days? Is the use decreasing, increasing or remaining the same? The hair test was negative but the person admits to taking X? The hair test was positive but the person says no way I don t do drugs? Could Y cause a positive result for X? The person collecting my hair contaminated it with drug? How long does X stay in body hair? What s the timeline? FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION 40

Thank you. Questions? james.bourland@alere.com aleretoxicology.com